Key facts
- Ensho Therapeutics’s last known valuation is $36.0M (Sep 2025).
- It has raised $27.9M; the latest was Early Stage VC ($22.5M) in Feb 2026.
- Notable investors include Avego Management, Global BioAccess Fund.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ensho Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Ensho Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ensho Therapeutics
Operator of a biopharmaceutical company intended to develop oral therapies for patients with inflammatory diseases. The company offers oral, selective small molecule inhibitors of lymphocyte homing integrin, a mechanism already validated by a commercially available antibody, enabling people who are suffering from inflammatory bowel disease to get treatment.
- Sector
- Healthcare
- HQ
- Morris Plains, NJ, United States
- Founded
- 2024
- Employees
- 11
- Website
- enshorx.com/
- Ownership
- Privately Held (backing)
Ensho Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ensho Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ensho Therapeutics in its N-PORT filings yet. We sweep new filings monthly.